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Abstract 
 The consumption of marine mussels as popular seafood has increased steadily over the past 
decades. Awareness of mussel derived molecules that promote health has contributed to extensive 
research efforts in that field. This review highlights the bioactive potential of mussel components 
from species of the genus Mytilus (e.g. M. edulis) and Perna (e.g. P. canaliculus). In particular, 
bioactivity related to three major chemical classes of mussel primary metabolites, i.e. proteins, 
lipids, and carbohydrates, is evaluated. Within the group of proteins the focus is mainly on mussel 
peptides e.g. those obtained by bio-transformation processes such as fermentation. In addition, 
mussel lipids, comprising polyunsaturated fatty acids (PUFAs), are discussed as agents well-known 
for the prevention and treatment of rheumatoid arthritis (RA). Within the third group of 
carbohydrates, mussel polysaccharides are investigated. Furthermore, the importance of monitoring 
the mussel as food material in respect to contaminations with natural toxins produced by microalgae 
is discussed. 
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1. Introduction 
It is predicted that, approximately 2,210,000 species exist in the ocean, from which only 
around 190,000 species have been catalogued so far (Mora et al., 2011). The phylum Mollusca 
represents one of the largest and most diverse groups of marine animals. The Bivalvia, a large class 
with around 20,000 species (Chapman, 2009) within Mollusca, includes some of the best known 
invertebrates such as clams, oysters, scallops, and mussels and is represented at all depths and in all 
marine environments. Molluscan shells, including those from bivalves, have been used as tools, 
containers, fetishes, and decorations since ancient times. Large populations, particularly those living 
in coastal areas, e.g. aboriginal groups, have relied on these animals for a substantial portion of their 
diet (Brusca & Brusca, 1990). Apart from the New Zealand green-lipped mussel, few reports 
available in the public domain deal with the traditional use of mussels against diseases. The sauce 
from a decoction of M. edulis, for instance, is traditionally used in China for its immune 
strengthening properties and to treat liver and kidney dysfunctions as well as impotence and 
menoxenia (Li & Ding, 2006). Nowadays, molluscan shellfish including bivalves are harvested 
commercially and are of considerable relevance for aquaculture industries worldwide. Farmed 
marine mussels from the Mytilidae family, comprising genera such as Mytilus and Perna, are 
popular in human diet, providing high levels of proteins, omega-3 polyunsaturated fatty acids 
(PUFAs), iodine, and carbohydrates.  
Considering the close relation between food and health, bioactive mussel components have 
proven to play a vital role for the development of functional foods, defined as food with specific 
beneficial health effect beyond simple nutrition, or nutraceuticals, describing a union between 
nutrition and pharmaceutics (Bernal et al., 2011; Haller, 2010; Lordan, Ross, & Stanton, 2011). 
Moreover, relatively high volumes of mussel wastes in aquaculture and processing, prompted 
researchers to focus on this underexplored source for bioactives (Harnedy & FitzGerald, 2012; Kim 
& Mendis, 2006). Over the past decades, bioactive properties of mussel components have been 
investigated by many researchers and several dietary supplements containing mussel extracts have 
been brought to the market. For example Lyprinol
®
, a dietary supplement product containing the 
lipid extract of the green-lipped mussel, Perna canaliculus, is sold almost worldwide as anti-
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inflammatory and anti-arthritic remedy. Hence, the importance of marine mussels as source for 
bioactive substances such as e.g. antimicrobial, anti-inflammatory as well as anti-cancer agents is 
increasing rapidly. In this review article, we focus on mussel primary metabolites comprising 
peptides, lipids, and carbohydrates considering their bioactive properties as well as different classes 
of shellfish toxins and their impact on human health. 
 
1.1. Literature search and data evaluation concerning mussel bioactives 
This review covers literature up to January 2013 and is based on the combination of surveys 
in three scientific databases, i.e. SciFinder Scholar (Chemical Abstracts Service - 
http://www.cas.org/products/sfacad/index.html), ISI Web of Knowledge (Thomson Reuters - 
http://www.webofknowledge.com), and Scopus (Reed Elsevier - http://www.scopus.com). The two 
most abundant mussel genera, i.e. Mytilus and Perna, were applied as key words and the retrieved 
references were further refined focusing on reported bioactivity. Figure 1 gives an overview on the 
number of publications dealing with mussel bioactives corresponding to three major primary 
metabolite classes, i.e. proteins/peptides/amino acids, lipids, and carbohydrates, as well as 
miscellaneous metabolites. Furthermore, selected publications were evaluated according to the type 
of bioactivity in relation to metabolite classes, revealing that most studies deal with antimicrobial 
mussel peptides or anti-inflammatory mussel lipids (Figure 2). 
 
Insert Figure 1 here. 
 
Insert Figure 2 here. 
 
1.2. Marine mussel species of interest: Morphology, geographical distribution, and habitat 
Marketed worldwide as live, frozen or processed seafood, marine mussels are native to both, 
northern and southern hemispheres. The mussel industry is split into two production techniques, i.e. 
bottom mussels, naturally grown on the seabed and harvested by specialised dredging equipment, 
and rope mussels, cultivated on rope structures in aquaculture (Gosling, 1992). In their natural 
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environment mussels have to adapt to parameters such as salinity, wave exposure, substrate, zone, 
height, temperature, and water quality. Most species tolerate a wide range of salinity. However, at 
very low salinities the mussel growth is limited, which leads to smaller sizes (Almada-Villela, 
1984). Mussels, occurring in low and mid intertidal areas, prefer sheltered places where individuals 
are usually attached to hard surfaces such as rocky substrates. In order to adhere to boulders, 
cobbles, or pebbles they use their byssal threads which are proteinaceous silk-like fibres also known 
as the mussel’s beard (Lee et al., 2011). The most limiting parameter for the distribution of marine 
mussels is the temperature, as some species prefer colder while some prefer warmer waters. 
Furthermore, the content of active metabolites varies with season, life cycle, and habitat (Freites, 
Fernandez-Reiriz, & Labarta, 2002). 
Commercially most relevant marine mussel species belong to the two genera of Mytilus and 
Perna. Mytilus species occur in temperate waters of Europe, Asia, and America, whereas Perna 
species are cultured in warmer waters such as Thailand, the Philippines, China, and New Zealand 
(Gosling, 1992). Within the genus Mytilus, the marine mollusc M. edulis, is commonly known as 
blue or black mussel (Figure 3A and 3B) due to the colour of its shell (size up to 100 mm in length). 
It is mostly cultured in Canada, USA, Europe, and Africa. Another common edible mussel, M. 
galloprovincialis, originates from the Mediterranean Sea. Interestingly, it is not possible to 
distinguish M. edulis and M. galloprovincialis based solely upon morphological characteristics 
(Gosling, 1992). Moreover, hybrids between the blue mussel and the Mediterranean mussel, have 
been reported in Ireland, western France, southwest England, and north Scotland (Gosling, Doherty, 
& Howley, 2008). Concerning the genus Perna, major aquaculture mussel species include P. viridis, 
the Asian green mussel, and P. canaliculus, the green-lipped mussel which is endemic to New 
Zealand (Figure 3C and 3D). The latter one is an integral dietary part of the indigenous Maori 
culture (Maori name: kuku) and is the basis of an important aquaculture and processing industry 
serving both export and domestic markets. Besides its green lip, it is characterised by a bright green 
stripe around the posterior ventral margin of the shell (size up to 240 mm in length) (Wakimoto et 
al., 2011). 
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Insert Figure 3 here. 
 
2. The bioactive potential of metabolites derived from marine mussels 
Most research groups focus on the evaluation of the bioactive potential of extracts, 
hydrolysates, or purified components derived from whole mussel meat, single organs, cell 
compartments, or blood. Mussel shells, produced in large amounts as terrestrial waste from 
aquaculture processing plants, are composed of organo-minerals such as aragonite and calcite as 
well as shell matrix proteins (Gosling, 1992; Marin et al., 2007). Since there is low evidence for 
bioactivity reported for shell components, this review will not focus on this part of the mussel. 
 
2.1. Bioactive proteins, peptides, and amino acids from marine mussels 
2.1.1. Generation of bioactive proteinaceous metabolites 
Mussels contain a large portion of muscle tissue with considerably high content of protein. 
Interestingly, the number of research publications reporting significant bioactivity exerted by high 
molecular weight proteins is very low. However, one of the rare examples for bioactive 
proteinaceous macromolecules is pernin (60 kDa), found in the cell-free haemolymph (plasma) of P. 
canaliculus. It is a self-aggregating glycosylated protein consisting of 497 amino acids resembling 
an anti-thrombin peptide known from terrestrial leeches. However, the anti-thrombin activity found 
for this mussel-derived protein is only weak (Scotti et al., 2001).  
To exert significant bioactivity, complex protein macromolecules usually need to be split 
into shorter chains of amino acids (peptides) either by processing techniques such as fermentation or 
by gastrointestinal digestion. Since ancient times, fermentation has been used as a method for food 
preservation by controlling the growth and multiplication of a number of pathogens. Still today it is 
popular as an affordable technology to enhance food safety but also to improve digestibility, taste 
and flavour of foods (Motarjemi, 2002; Visessanguan et al., 2004). Fermented fish and shellfish 
sauces are used as nutritional condiments in various cuisines, e.g. in African and South East Asian 
countries. During fermentation, bioactive peptides or amino acids are enzymatically produced from 
large precursor or parent proteins which usually show only weak or no bioactivity. The underlying 
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biochemical process of fermentation which depends on temperature, pH, and time, is called 
hydrolysis or proteolysis, respectively. The cleavage of proteins is either catalysed by endogenous 
and/or exogenous enzymes which can be inactivated by heat treatment in order to terminate the 
process. Although favoured as a low cost option, the use of endogenous proteases which are already 
present in food matrices, such as shellfish meat, has the disadvantage of long time periods required 
to obtain desired bioactive peptides. The production of fermented blue mussel sauces (FBMSs) 
requires six to twelve months of fermentation (Jung, Rajapakse, & Kim, 2005). Usually, this so-
called autoproteolysis takes place in brine or salt solution (above 20% NaCl, w/w) to avoid 
microbial contamination during long time periods. The downside of these fermented products is the 
high salt content, which is unfavourable especially for consumers with risk factors for cardiovascular 
diseases. However, electrodialysis can be used as a method to reduce the amount of salt (Park, Je, & 
Kim, 2005). 
Despite higher costs, commercial enzymes are preferred to endogenous proteases, due to 
faster reaction rates and much shorter fermentation time frames. By the use of food-grade enzymes 
such as alcalase, neutrase, papain, trypsin, Protamex
®
, and Flavourzyme
®
, precursor proteins can be 
cleaved within an average of 30 minutes of hydrolysis (Dai et al., 2012). Moreover, the use of well-
characterised commercial enzymes allows a better control over protein breakdown, molecular 
weight, and composition of generated peptides. 
 
2.1.2. Purification techniques and characterisation of proteinaceous metabolites 
To gain insights into putative health effects of proteinaceous metabolites, these are either 
investigated in the form of hydrolysate mixtures from fresh, homogenised mussels or as isolated and 
purified amino acids, proteins, or peptides. Besides desired bioactive peptides or amino acids, 
generated hydrolysates also contain non-proteinaceous components or inactive protein 
macromolecules. Methods of choice to purify hydrolysate mixtures and to obtain specific peptide 
classes according to their molecular weight include e.g. centrifugation or ultrafiltration using 
appropriate membranes. To achieve further separation these procedures are followed by gel and ion 
exchange chromatography techniques as well as RP-HPLC (Ngo et al., 2012; Silva, Park, & 
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Hubinger, 2010). However, separation is not always beneficial in respect to bioactivity. In some 
cases mixtures of peptides, amino acids, and sugars show higher bioactivity (e.g. antioxidant 
activity) than single purified peptides (Sarmadi & Ismail, 2010). 
Some peptides, such as antimicrobial peptides (AMPs, see below) are naturally available in 
the mussel, hence, there is no need for time-consuming processes to break down larger proteins to 
obtain these bioactive peptides. As highlighted by Charlet and co-workers (1996), peptide extraction 
and purification protocols for AMPs generally include the suspension of homogenised mussel meat, 
blood or haemolymph in acidic aqueous solutions. In further bioactivity-guided steps the mixture is 
usually centrifuged and the supernatant is subjected to solid phase extraction followed by RP- and 
gel permeation HPLC (Charlet et al., 1996). In order to check the purity and/or molecular weight of 
peptides electrophoresis (e.g. SDS-PAGE) or ESI-QTOF tandem mass analyses are performed. In a 
final step, primarily automated Edman degradation or sequencing is used to elucidate amino acid 
sequences (Charlet et al., 1996; Jung & Kim, 2009). To date, the 3D structures of only very few 
mussel peptides have been completely resolved by NMR techniques, i.e. the AMPs MGD-1 (Yang et 
al., 2000) and mytilin B (Roch et al., 2008). Furthermore, knowledge about characteristic structural 
features, e.g. special loop regions, gives further insights into requirements necessary for observed 
bioactivities (Romestand et al., 2003). Despite the availability of advanced molecular techniques 
such as expressed sequence tag analyses and gene cloning, the identification of further bioactive 
mussel peptides and the investigation of their sequential properties as well as structural features still 
appear as new area of research. 
 
2.1.3. Potential health benefits and biological properties of proteinaceous metabolites 
In general, bioactive peptides derived from marine mussels contain 5 to 40 amino acid 
residues. Depending on the amino acid sequence and structural properties, major biological effects 
of mussel peptides include antimicrobial, antihypertensive, and anticoagulant activities (Je et al., 
2005; Jung & Kim, 2009; Löfgren et al., 2008). An overview on bioactive mussel 
proteins/peptides/amino acids is given in Table 1. 
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Insert Table 1 here. 
 
2.1.3.1. Antimicrobial peptides (AMPs) 
In the field of molecular cell biology, AMPs comprise the most studied group of peptides 
from marine mussels. Only recently, AMPs have attracted the attention of medicinal chemists for 
exploitation as novel drug candidates in the treatment of infectious diseases in humans (Otero-
Gonzalez et al., 2010; Sperstad et al., 2011). As mentoned above, AMPs are natural peptides (not 
enzymatically hydrolysed) which are expressed by the mussel itself as part of its haemolymph, the 
specific innate immunodefense system. AMPs might be the reason that mussels seem to be less 
affected by diseases compared to other bivalve molluscs (Gestal et al., 2008). AMPs show 
antifungal, antibacterial, or antiviral effects (Charlet et al., 1996; Mitta et al., 1999; Yasin et al., 
2000) and act via binding to microorganisms, by means of electrostatic interaction with cell wall or 
membrane residues, promoting their elimination through different mechanisms (Jenssen, Hamill, & 
Hancock, 2006). These types of amphipathic, cationic peptides defined by a molecular weight <10 
kDa, are also widespread among insects (Hancock & Scott, 2000; Steiner et al., 1981). According to 
their secondary structure, AMPs can be categorised into three major groups, i.e. (i) linear α-helical 
peptides, (ii) cysteine-rich peptides containing β-sheets and disulfide bonds, and (iii) peptides with 
an over-representation of certain amino acids (Yasin et al., 2000; Zasloff, 2002). 
Among different species of marine mussels, AMPs have primarily been identified in two 
species of the Mytilus genus and one species of the Perna genus. AMPs comprise multiple isoforms 
in six families, i.e. defensins, mytimycins, myticins, mytilins, big defensins, and mytimacins, which 
mostly belong to the group of cysteine-rich peptides usually showing several disulfide bonds 
(Charlet et al., 1996; Gerdol et al., 2012; Löfgren et al., 2009; Mitta, Vandenbulcke, et al., 2000). 
About 15 years ago, isolation and characterisation of AMPs from marine mussels (Table 1) 
began with the identification of mytimycin (6.5 kDa), defined by twelve cysteine residues, as a first 
solely antifungal molecule from the blood of M. edulis (Charlet et al., 1996; Sonthi et al., 2011). 
Further isolated AMPs are generally smaller (3.7 – 4.5 kDa), positively charged and amphiphilic. 
The two representatives defensin A and B (Table 1), for instance, were purified from M. edulis 
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comprising six cysteine residues (Charlet et al., 1996). The defensins MGD-1 and MGD-2 (Mitta, 
Vandenbulcke, et al., 2000; Romestand et al., 2003) and the family of myticins (A, B, and C), found 
in M. galloprovincialis, show eight cysteine residues engaged in four intramolecular disulfide bonds 
(Hubert, Noel, & Roch, 1996; Mitta et al., 1999). Furthermore, five AMP isoforms of mytilins were 
identified (A, B, C, D and G1). Mytilin A and B were first isolated from M. edulis (Charlet et al., 
1996) and mytilin B, C, D, and G1 originate from M. galloprovincialis (Mitta, Vandenbulcke, et al., 
2000). 
Apart from mytimycin which exerts only antifungal effects, members of all Mytilus AMP 
families show a broad-spectrum activity against Gram-positive (e.g. S. aureus) and Gram-negative 
(e.g. E. coli) bacteria in liquid growth inhibition assays (Charlet et al., 1996; Hubert, Noel, & Roch, 
1996; Mitta, Vandenbulcke, et al., 2000). As in the case of mytilin B and D (Mitta, Vandenbulcke, et 
al., 2000), myticin B (Mitta et al., 1999), and defensin MGD-1 (Mitta et al., 1999), these 
antibacterial effects are accompanied with considerable antifungal activity (e.g. against Neurospora 
crassa and Fusarium oxysporum). Mytilin A has also been tested against fish viral pathogens and 
protozoan parasites (Carriel-Gomes et al., 2007; Löfgren et al., 2008). However, in both cases it was 
only active at near cytotoxic concentrations. 
Concerning AMPs originating from Perna species, much less information is available in the 
literature (Table 1). To our best knowledge, only one AMP (9.7 kDa) was reported from the gill 
extract of P. viridis, the greenshell mussel occurring in the region of Hong Kong. This peptide 
exhibited distinct antibacterial (against S. aureus) and antifungal (against A. flavus) activity by 
comparing the zone of inhibition with either erythromycin or fluconazole as positive control using a 
standardized single disc method (Chandran, Rameshkumar, & Ravichandran, 2009). 
 
2.1.3.2. Antioxidant and antihypertensive peptides 
Several studies on fermented or similarly processed marine mussels focus on the 
investigation of health beneficial bioactive properties of the derived peptides. Major effects include 
antihypertensive and antioxidant activity as well as radical scavenging capacity. For example, 
Korean researchers identified an antihypertensive and two antioxidant peptides from the sauce of 
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fermented M. edulis (Je et al., 2005; Jung, Rajapakse, & Kim, 2005; Rajapakse et al., 2005). One of 
these purified peptides (6.5 kDa; N-terminal amino acid sequence EVMAGNLYPG; Table 1) 
exhibits angiotensin I converting enzyme (ACE) inhibition with an IC50 value of 19.34 µg/mL (= 
2.98 µM) in a spectrophotometric assay (Cushman & Cheung, 1971; Je et al., 2005). For this peptide 
effective blood pressure lowering effects were confirmed in an in vivo model using spontaneously 
hypertensive rats. Further two isolated peptides which have a much smaller size of 962 Da and 620 
Da respectively (Table 1), were found to exhibit radical scavenging properties in a lipid peroxidation 
inhibitory assay. The first one (MRSP; 962 Da; sequence HFGDPFH; Table 1) was able to scavenge 
a variety of radicals (superoxide, hydroxyl, carbon-centred, DPPH) with IC50 values in a range 
between 21 and 96 µM, whereas no IC50 values were reported for the latter one (620 Da; FGHPY; 
Table 1). In terms of lipid peroxidation both peptides showed a strong inhibition which was higher 
than that observed for the natural antioxidant α-tocopherol, the reference substance (Jung, 
Rajapakse, & Kim, 2005; Rajapakse et al., 2005). Another potent antioxidant mussel peptide with 
the amino acid sequence LVGDEQAVPAVCVP, characterised by a low molecular weight of 1.6 
kDa, was identified from M. coruscus using an in vitro gastrointestinal digestion system (Jung et al., 
2007). This peptide showed higher protective activity against lipid peroxidation in a linoleic acid 
model system than vitamin C and α-tocopherol. 
In another study, Dai and co-workers analysed the ACE inhibiting effect of M. edulis protein 
hydrolysates obtained by enzymatic processing using six different food-grade proteases (Dai et al., 
2012). As a result, the hydrolysates produced by alcalase (peptide molecular weights <1,000 Da) 
revealed the highest inhibition on ACE with an IC50 value of 66.3 µg/mL. The contained antioxidant 
or antihypertensive peptides are suggested to find further applications in food preservation as 
alternative to synthetic additives or in pharmaceutical industries to avoid lipid peroxidation (Jung, 
Rajapakse, & Kim, 2005; Rajapakse et al., 2005). 
 
2.1.3.3. Other biological effects related to marine mussel proteins and peptides 
Besides AMPs, antioxidant and antihypertensive peptides, mussels provide a source for 
further bioactive proteinaceous compounds. For example, an oligopeptide with a potent dose-
 12 
dependent anticoagulant activity has been isolated from M. edulis (Jung & Kim, 2009). This 
oligopeptide, named M. edulis anticoagulant peptide (MEAP), is characterised by a molecular 
weight of 2.5 kDa. MEAP is able to prolong the thrombin time as well as the activated partial 
thromboplastin time and interact with key blood coagulation factors (Jung & Kim, 2009). 
Furthermore, a recent publication reports anti-inflammatory properties for extracts from M. 
galloprovincialis containing fifteen essential and non-essential amino acids quantified by GC-MS 
(Badiu et al., 2010). In this work, Badiu and colleagues observed enhanced dermal and epidermal 
neoformation in an in vivo model for skin burns that suggests further development of mussel derived 
proteic extracts for therapeutic applications. 
Another part of the mussel which has already been intensively investigated in the direction of 
applied research is its byssus. Since mussels grow in intertidal zones they are exposed to harsh 
waves. These circumstances have driven the development of strong adhesive byssal threads in order 
to brave the elements. The adhesive power of mussels has been the subject of numerous studies 
trying to synthetically mimic these characteristics in polymers used for surgical applications, 
technology, and industry (Brubaker & Messersmith, 2012; Lee et al., 2011). Adhesive protein 
extracts from M. edulis byssus, for instance, have shown promising results as moisture-resistant 
biocompatible curing agents. In an experimental model, they were shown to form strong bonds 
between two overlapping strips of porcine small intestinal submucosa (Ninan et al., 2007). These 
findings will clearly drive future efforts to develop new mussel-inspired materials especially for wet 
adhesion necessary for surgical applications to coat, heal, or seal tissues. 
 
2.2. Bioactive lipids and non-polar components from marine mussels 
2.2.1. Isolation, purification and characterisation of lipid metabolites 
Among the three major groups of mussel primary metabolites, lipids have so far shown the 
highest potential for the commercial development of health beneficial functional foods or dietary 
supplements. Mussel lipid extracts and fractions can be obtained by solvent extraction and are 
purified by chromatographic separation. The increasing instability during purification processes 
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limits the investigation of single lipid components, hence analyses mostly focus on the 
characterisation of lipid extracts or fractions rather than pure compounds. 
Mussel lipid extracts are usually obtained by extraction of fresh or freeze-dried mussel meat. 
By means of enzymatic (e.g. using lipase or protease) or chemical (e.g. KOH) hydrolysis complex 
lipids are cleaved to obtain e.g. single fatty acids. In general, normal phase column chromatography 
is subsequently used to fractionate the crude extracts into major lipid classes, i.e. sterol esters, 
triglycerides, free fatty acids, sterols, and phospholipids. In some cases, purification and structural 
analysis is also pursued and achieved by chromatographic techniques such as preparative TLC 
(McPhee et al., 2010). GC, GC-FID, or GC-MS techniques are the most suitable methods for the 
characterization of fatty acids present in mussel oils. Classically, lipid classes have to be hydrolysed 
and methylated to obtain fatty acid methyl esters (FAMEs). Subsequently, identification of lipid 
components is carried out by comparison to known standards. 
 
2.2.2. Bioactive marine oils from the New Zealand green-lipped mussel P. canaliculus 
Several anti-inflammatory and anti-arthritic dietary supplements which contain mussel lipids 
are available commercially. The best known products are Seatone
® 
and
 
Lyprinol
®
. Their 
development was inspired by the observation of the New Zealand Maori population living in coastal 
areas that consume a high amount of green-lipped mussels (P. canaliculus) in their diet. These 
people develop osteoarthritis (OA) to a much lesser extent than inland Maoris. In 1976, Seatone
® 
was launched
 
as the first commercially available anti-arthritic green-lipped mussel product 
(McFarlane & Croft, 1980). In early years, stability problems of this freeze-dried mussel extract 
strongly affected the level of anti-inflammatory activity and raised concerns among consumers and 
industry. To overcome these issues, 3% tartaric acid was added directly after shucking the mussel as 
antioxidant and metal chelator which resulted in consistently high anti-inflammatory effects 
(Halpern, 2000; Whitehouse et al., 1997). Subsequently, the formulation method was improved and 
in 1998, Lyprinol
®
 was brought to the market as another anti-inflammatory marine mussel product. 
It contains the oil of P. canaliculus obtained by supercritical fluid extraction (CO2-SFE) of the 
stabilised, freeze-dried mussel powder formulated with olive oil and vitamin E as an antioxidant 
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(Singh et al., 2008; Whitehouse et al., 1997). By using this technique and CO2 as extracting medium, 
the material is not exposed to high temperatures, hence a mild extraction is achieved without 
activating lipid degrading enzymes such as phospholipases and lipoxygenases (Wakimoto et al., 
2011). Since there are no organic solvents present during this extraction process, it is considered as 
food-friendly. 
Lipid classes present in mussel oil comprise sterol esters, triglycerides, free fatty acids 
(saturated and unsaturated), carotenoids, sterols and polar lipids (Sukumaran et al., 2010). In total 
there are 90 fatty acid components reported for Lyprinol
® 
(Murphy et al., 2002). Omega-3 
polyunsaturated fatty acids (PUFAs) with 13% eicosapentaenoic acid (EPA) and 21% 
docosapentaenoic acid (DHA) are found as major ingredients (Murphy et al., 2002). Furthermore, 
novel anti-inflammatory omega-3 PUFAs, i.e. 5,9,12,15-octadecatetraenoic acid, 5,9,12,16-
nonadecatetraenoic acid, 7,11,14,17-eicosatetraenoic acid, and 5,9,12,15,18-heneicosapentaenoic 
acid have been purified by normal and reversed phase chromatography and identified by GC-MS 
(Singh et al., 2008; Treschow et al., 2007). Figure 4 gives an overview on main and novel PUFA 
structures present in P. canaliculus oils. The nomenclature of these fatty acids is based on the 
number of carbon atoms and the number of their double bonds. Basically PUFAs are categorised in 
the omega-6 and the omega-3 class. Omega-6 PUFAs are found mainly in plants and are contained 
in vegetable oils, whereas omega-3 PUFAs are found in fish and shellfish and occur to a lesser 
extent in plants. In terms of bioactivity, the omega-3 PUFAs originating from fish and shellfish 
sources are considered to be more efficient in their biological activity than those found in plants 
(Chan & Cho, 2009). 
 
Insert Figure 4 here. 
 
The anti-inflammatory mode of action of the green-lipped mussel oil has been linked to its 
ability to inhibit the production of inflammatory mediators by affecting key enzymes in the 
arachidonic acid (AA) cascade (Figure 5) (McPhee et al., 2007; McPhee et al., 2010). AA is 
metabolised via well characterised pathways including cyclooxygenase (COX) and lipoxygenase 
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(LO) enzymes. As a result, pro-inflammatory (e.g. prostaglandins), chemotactic, broncho-
constricting (e.g. leukotrienes), or potential tumour promoting (e.g. 5-hydroxyeicosatetraenoic acid 
(5-HETE)) agents are produced. Due to their structural similarity to AA (Figure 4), mussel PUFAs 
like EPA and DHA can act as competitive substrates for these key enzymes and thus reduce 
inflammatory responses. For example, the production of prostaglandin E2 (PGE2) is inhibited by 
Lyprinol
® 
with an IC50 of 1.2 µg/mL (Whitehouse et al., 1997). Furthermore, the efficacy of 
Lyprinol
® 
for the treatment of chronic airway inflammation was also demonstrated in a study with 
patients with atopic asthma (Emelyanov et al., 2002).  
 
Insert Figure 5 here. 
 
As opposed to conventional therapeutic treatment options such as non-steroidal anti-
inflammatory drugs (NSAIDs), the use of above discussed mussel oil products as natural remedies 
against arthritis causes very few side effects. Rapid-acting NSAIDs are well known for their adverse 
effects in the gastro-intestinal system due to non-selective inhibition of COX enzymes, related 
deficiency in cytoprotective prostaglandins, and subsequently reduced mucous production leading 
e.g. to the development of gastric ulcers (Toki et al., 2007). In contrast, green-lipped mussel 
preparations demonstrate in vivo gastro-protective effects (Rainsford & Whitehouse, 1980). 
Lyprinol
® 
does neither affect platelet aggregation nor the natural resistance of the stomach mucosa 
in humans which is related to the involvement of the inducible COX-II rather than COX-I 
(Whitehouse et al., 1997). P. canaliculus lipid extracts
 
inhibit COX-I and COX-II by 12% and 25%, 
respectively (McPhee et al., 2007). Hence, these mussel oils are mainly suitable for the treatment of 
chronic inflammation. This further explains that the mentioned mussel products show no or modest 
activity on the carrageenan-induced paw oedema assay in rats, an experiment which is typically used 
to evaluate acute inflammation (Whitehouse et al., 1997). 
In a recent study, McPhee and co-workers (2007) compared in vitro COX-inhibiting effects 
of Lyprinol
®
 and the total lipid extracts obtained from P. canaliculus and M. edulis before and after 
KOH-, protease-, or protease-lipase-hydrolysis (McPhee et al., 2007). The non-hydrolysed total lipid 
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extracts of both P. canaliculus as well as M. edulis showed a moderate COX inhibition. Related to 
an increase of free fatty acids, a strong COX inhibition was observed after saponifying the extracts 
by KOH hydrolysis. Except for higher lipid contents in P. canaliculus, there were no significant 
differences observed between the two mussel species. Interestingly, also Lyprinol
® 
has demonstrated 
a 10-fold higher inhibition of both COX isoforms after hydrolysis (McPhee et al., 2007). 
A recent study provided mechanistic insights into the anti-inflammatory effects of Lyprinol
®
 
in the arachidonic acid cascade. (Lee et al., 2008) Lee and co-workers (2008) investigated protein 
expression profiles of splenocytes in rats with adjuvant-induced arthritis (AIA). In AIA rats 
consuming Lyprinol
®
 orally, they found that six metabolism-related proteins are down-regulated 
while malate dehydrogenase (MDH), a key enzyme in gluconeogenesis, is up-regulated. Hence, the 
level of glucose necessary for Major-Histocompatibility-Complex I (MHC-I) activation is decreased 
which underlines the anti-inflammatory mechanism of Lyprinol
®
, since an activated MHC-I is 
involved in the development of autoimmune diseases. These findings indicate that Lyprinol's anti-
inflammatory activity is mediated by multiple mechanisms, which are still not fully evaluated. 
Since their launch in 1976, effects of nutritional green-lipped mussel supplement products on 
osteoarthritis (OA), rheumatoid arthritis (RA), asthma, and cancer have been studied in various 
clinical trials and discussed in numerous review papers (Brien et al., 2008; Doggrell, 2011; Gibson 
et al., 1980; Gibson & Gibson, 1998; Lau et al., 2004; Sukumaran et al., 2010). Within its main field 
of application, i.e. in patients suffering from OA or RA, outcomes of most studies have proven a 
reduced amount of pain and stiffness related to the intake of mussel preparations (Halpern, 2000). 
Apart from orally applied Lyprinol
®
 capsules, also topical preparations such as skin cream 
containing mussel lipids seem to be effective against OA and RA (Chandler, 2005a, 2005b; 
Kenneth, Waite, & Downs, 2009; Mulye & Assoulin, 2012; Williams & Sansom, 2008). However, 
to our knowledge no comparative study has been conducted to evaluate the efficacy of orally versus 
topically applied mussel lipids.  
 
2.2.3. Bioactive marine oils from Mytilus species 
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In contrast to lipids from Perna species, the amount of information available on mussel lipids 
from Mytilus species is comparably small. In general, Mytilus oils are known to contain similar 
major long chain omega-3 PUFAs (EA, EPA and DHA) as Perna oils, however, in considerably 
lower yields (McPhee et al., 2007; McPhee et al., 2010). Anti-inflammatory effects were found for 
both non-hydrolysed M. edulis crude lipid extracts and hydrolysed triglyceride fractions (Christie, 
1982; McPhee et al., 2010). Especially after saponification of the crude extracts, containing EPA and 
DHA at a percentage of 37% of total fatty acids, inhibition of leukotriene production was observed 
in a neutrophil 5-LO assay in vitro and in an AIA rat model (McPhee et al., 2010). Combined with 
the 5-LO inhibition the total free fatty acid fractions show a selective in vitro inhibition of COX-II 
(McPhee et al., 2007). Moreover, since there were no negative side effects observed in animal 
models, the findings of McPhee and colleagues suggest the potential of M. edulis lipid extracts or 
fractions as anti-inflammatory agents. 
Further Mytilus species reported to contain bioactive lipids comprise the Korean mussel, M. 
coruscus and the Mediterranean mussel, M. galloprovincialis. Different M. coruscus lipid extracts 
obtained by suspension in organic solvents (MeOH, chloroform, hexane) or solvent mixtures 
(MeOH:chloroform, MeOH:hexane) were analysed for their potential to induce apoptosis of several 
cancer cells including human prostate, breast, lung, and liver cancer cell lines. As a result, the 
hexane extract was found to possess the highest in vitro anti-tumour effects by inducing apoptosis of 
human prostate cancer cells (Kim et al., 2011). Interestingly, the most active fraction of the hexane 
extract of this Korean mussel was found to contain remarkably high 33.4% of EPA. In another 
study, Badiu and colleagues investigated the wound healing potential of M. galloprovincialis lipid 
extracts obtained from extractions with chloroform:MeOH (1:2; v/v). A positive effect on burnt skin 
was confirmed in an animal model using Wistar rats, suggesting further development of these 
extracts for skin-care products (Badiu et al., 2008). 
 
2.2.4. Isolated single lipid components from marine mussels 
Bioactivity studies on marine lipids are usually carried out on extracts or fractions rather than 
pure compounds. As mentioned before, this might be due to the increasing instability of fatty acids, 
 18 
for instance, during isolation processes. In a very recent study, Wakimoto and colleagues (2011) 
detected unstable anti-inflammatory and antioxidant furan fatty acids (Figure 4) in the green-lipped 
mussel, P. canaliculus. After semisynthetic stabilisation, one of the furan fatty acid ethyl esters 
showed an even higher anti-inflammatory potential than EPA ethyl ester in an in vivo model of AIA 
(Wakimoto et al., 2011).  
Another rare example for an isolated single lipid compound is lysolecithin. This hydrophilic 
phospholipide belongs to the class of phosphatidylcholines and was identified as anti-histaminic and 
anti-inflammatory component in P. canaliculus lipid fractions in the mid 1980s (Kosuge et al., 
1986). However, no further studies have been undertaken to pursue these results. 
 
2.3. Bioactive carbohydrates from marine mussels 
2.3.1. Structural characteristics and analysis of mussel carbohydrates 
The group of mussel carbohydrates is primarily represented by polysaccharides. These sugars 
are composed of monosaccharides which are connected via glycosidic bonds forming linear or 
branched macromolecules (average molecular weight 1.5 x 10
6
 Da). It is distinguished between 
homo- (one type of monosaccharide) and heteropolysaccharides (different types of 
monosaccharides). In some cases sugar components are covalently linked to polypeptide side chains 
of cell wall proteins. These so-called glycoproteins are important for the invertebrate’s immune 
system (Smital & Kurelec, 1998). In general, carbohydrates can be extracted from the mussel by 
using different organic solvents. In most cases they are obtained by hot-water extraction followed by 
further purification steps including anion-exchange and gel-permeation chromatography (Miller et 
al., 1993). 
Techniques such as dialysis and lyophilisation allow a coarse fractionation of the sugar 
components. Isolation and purification is usually achieved by the use of molecular-sieve or affinity 
chromatography (Ovodova et al., 1992). An array of different techniques such as complete 
hydrolysis, periodate oxidation, methylation analysis, Fourier transform infrared spectroscopy 
(FTIR), and NMR, are applied in a final step to elucidate the structure of the carbohydrate of 
interest. 
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2.3.2. Bioactivities related to mussel carbohydrates 
Among the three major bioactive primary metabolite classes from mussels, the least attention 
has been paid to the group of carbohydrates, hence only very few research articles are available in 
the literature. In 1992, Ovodova and co-workers reported a high immunomodulating activity for 
mytilan, a branched bioglycan isolated from Crenomytilus grayanus, a marine mussel originating 
from Japan (Ovodova et al., 1992). Mytilan is a non-covalently linked complex of 95% 
polysaccharide and 5% protein with lectin (carbohydrate-binding) properties. The polysaccharide as 
the carbohydrate part consists of α-D-glucan similar to glycogen, an equivalent to starch which is 
known as an energy storing molecule in plants. Sonication of mytilan resulted in a mixture of 
glucose, maltose, and malto-oligosaccharides. Further NMR-based analyses of mytilan revealed an 
even higher degree of branching than glycogen (Ovodova et al., 1992). 
In another study, a glycogen was isolated from P. canaliculus and investigated in an in vivo 
model in rats with a carrageenin-induced footpad oedema where it was given i.v. and showed a 
dosed-dependent anti-inflammatory activity (Miller et al., 1993). However, this activity could no 
longer be observed after treatment with KOH or proteinase K suggesting that the anti-inflammatory 
properties are mediated by proteinaceous moieties associated with the macromolecule glycogen 
(Miller et al., 1993). 
Recently, Xu and colleagues published a work on the isolation and characterisation of the 
antioxidant polysaccharide MP-I (composed of glucose monomers) from M. coruscus (Xu et al., 
2008). It was found to be an α-(14)-D-glucan, branched with a single α-D-glucose at the C6 
position every eighth residue along the main chain (Xu et al., 2008). This molecule (1.35 x 10
6
 Da) 
exhibited a protective effect on acute liver injury in mice given intraperitoneally. MP-1 has been 
shown to inhibit lipid peroxidation which is involved in tissue damage during hepatic failure. The 
observed bioactivities render MP-I as beneficial marine mussel carbohydrate which may find 
pharmaceutical applications in humans (Xu et al., 2008). Cheng and co-workers (2010) have 
evaluated the impact of several extraction methods (by using water, acidic, or alkaline extracting 
media) on the antioxidant activity of mussel polysaccharides. A dose-dependent antioxidant activity 
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was detected for all mussel extracts in an in vitro spectrophotometric assay, with water and alkaline 
extracts being the most active (Cheng, Yu, & Zhang, 2010). 
 
2.4. Miscellaneous bioactive compounds from marine mussels 
Our literature survey suggest that the most bioactive marine mussel compounds can be 
classified as typical primary metabolites such as the discussed proteins, lipids, or carbohydrates. 
However, MytiLec, a sugar-binding protein (lectin) isolated from the mussel M. galloprovincialis, is 
discussed here under miscellaneous compounds due to its carbohydrate-binding properties. Recently, 
this compound was discovered by Japanese researchers as a 17 kDa α-D-galactose-binding lectin 
comprising a novel primary structure which is expected to promote research not only in the field of 
glycobiology (Fujii et al., 2012), but also in pharmacology. MytiLec belongs to the humoral defense 
factors of the mussel similar to AMPs (Casas et al., 2011). In terms of bioactivity, it exhibits a dose-
dependent cytotoxic effect on human Burkitt’s lymphoma Reji cells (Fujii et al., 2012). These results 
give insights into possible anti-cancer applications and will also help to reveal the physiological role 
of this novel galactose-binding lectin. 
 
3. Biotoxins affecting marine mussels 
Besides the beneficial effects and bioactives that mussel components may yield, it is vital to 
also consider potential harmful biotoxins that may be present in mussels. Mussels in common with 
other bivalve molluscs are filter-feeders. They can filter up to eight litres of sea water per hour 
whereby they derive their nutrition by passing water over their gills and extract and sort particles of 
food during this process (Jones, Richards, & Southern, 1992). They selectively choose filtered 
particles based on size and eject non-edible particles as pseudo-faeces before they enter the digestive 
tract. A large component of the ingested particles comprise of nutrient rich eukaryotic microalgae, 
mostly diatoms and dinoflagellates (Newell & Shumway, 1993). In marine environments there are a 
small but significant group of microalgae referred to as harmful algal bloom (HAB) species that 
cause injury to human health or socioeconomic interests, or to components of aquatic ecosystems 
(Anderson, Cembella, & Hallegraeff, 2012). Mussels are fairly non-discriminatory towards the 
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species of microalgae that they ingest. Their target feed can include a number of different HAB 
species that contain various compounds that are toxic to humans, and filter feeding shellfish 
including mussels are a significant source by which these toxins find a pathway through the food 
chain at concentrations that can cause human illness. 
HAB toxins have typically been classified based on the illness that they produce in human 
consumers; amnesic shellfish poisoning (ASP), ciguatera fish poisoning (CFP), diarrhetic shellfish 
poisoning (DSP), neurotoxic shellfish poisoning (NSP), paralytic shellfish poisoning (PSP), and 
azaspiracid shellfish poisoning (AZP). In addition there are other toxins that have yet to demonstrate 
adverse effects (acute or chronic) in humans including the Cyclic Imines Group, Pectenotoxins 
(PTX) Group and Yessotoxins (YTX) Group (UNESCO, 2005). Within these groups there are a 
large number of toxins differing in their structures, solubility and mode of action. In addition, a wide 
range of metabolites is found in shellfish due to biotransformation through enzymatic reactions. 
The majority of human diseases associated with HAB toxins appear to be acute phenomena, 
although some can cause prolonged chronic disease (e.g. ASP). Toxins from the PSP, DSP and ASP 
groups are considered to have a worldwide distribution and their causative species are also known to 
have global distribution (Ciminiello & Fattorusso, 2004). The micro-algae responsible for the 
remaining toxins are less cosmopolitan and their toxins are more restricted geographically. The 
distribution can however at best be described as patchy in a biogeographical sense, and this is 
compounded by variation in biotransformation of the parent toxin into chemical analogs that may be 
more or less toxic as they pass through the food web. There is also evidence of transfer of HABs by 
anthropogenic and non-anthropogenic vectors and this can result in toxins appearing in previously 
toxin free areas so the potential for toxic HAB species is to be regarded as potentially worldwide 
(Bolch & de Salas, 2007). 
The classification of toxins based on symptomology has been greatly advanced with the 
introduction of high-resolution analytical separation and detection technologies including HPLC 
combined with MS and NMR technologies. This has resulted in several prominent groups of toxins 
which can be summarised as (a) linear and macrocyclic polyethers, e.g. okadaic acid or 
dinophysistoxins; (b) ladder-frame polyethers, e.g. ciguatoxins and brevetoxins; (c) macrocyclic 
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imines, e.g., spirolides and gymnodimine; (d) tetrahydropurines, e.g., saxitoxin and analogs; and (e) 
toxic secondary amines, including domoic acid (Figure 6). 
 
Insert Figure 6 here. 
 
At present, there are no practical solutions to removing these toxins from shellfish other than 
allowing them to naturally depurate by metabolic processes within the shellfish growing area. This 
can take between several weeks to several months depending on the level of toxin and 
environmental parameters. The primary preventive tool for intoxications with natural toxins is the 
monitoring of toxin levels in algae in the harvesting areas. Based on the presence of toxins, 
restrictions can be placed and harvesting of shellfish forbidden if levels of toxin are too high. 
 
4. Conclusion and outlook 
Unlike other molluscs such as oysters, marine mussels are generally resistant to diseases (Gosling, 
1992). Harsh environmental conditions and challenges might be prompting the ability of the mussel 
to produce bioactives. Within the past decades, marine mussels, in particular species of the genera 
Mytilus and Perna, have been investigated for their primary metabolites. In addition as highlighted 
in this review, monitoring the mussel for possible contaminations with harmful biotoxins is of great 
importance for public health and product development. Driven by both industry and academia, 
prospecting a tremendous potential in the development of functional foods and nutraceuticals, 
research has been mainly directed towards the bioactive potential of proteins, lipids, and 
carbohydrates. As opposed to natural product drug discovery programmes which are usually aiming 
at the discovery of small molecules or secondary metabolites, the investigation of bioactive primary 
metabolites is a research area scattered over several scientific disciplines often accompanied by a 
lack of target-oriented strategies for analytics, isolation, and characterisation procedures for 
compounds of interest. To overcome these issues it might be of relevance to cross frontiers between 
chemistry and food industry in order to successfully use the gained knowledge about bioactives from 
marine mussels. As witnessed in a growing number of cases and especially in light of current 
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European legislations concerning aquaculture waste regulations a huge commercial interest 
facilitates such endeavours. 
Since protein accounts for the major part of mussel meat it is not surprising that a significant 
percentage of bioactives is found among proteins, peptides and amino acids. The advantages of this 
are reflected in a win-win situation for both industry and academia. Considering prospering 
aquaculture businesses producing large volumes of mussel waste materials, the generation of 
bioactive proteinaceus metabolites helps to exploit these waste materials and offers sources for the 
development of functional foods or nutraceuticals. However, challenges such as stability problems 
and the finding of suitable food-grade formulation methods require interdisciplinary expertise. For 
instance, as part of their immune system mussels produce a wide range of AMPs which have been 
mostly characterised by environmental biologists to evaluate the mussel's physiological functions. 
Since the emergence of resistance developed by microorganisms against state of the art treatment 
options, AMPs from marine mussels might also be considered as valuable source for therapeutics. In 
aquaculture, AMPs have been proposed as natural antimicrobial agents for the treatment of 
infectious diseases in marine species (Balseiro et al., 2011). Moreover, AMPs show a great potential 
as a natural antimicrobial food additive for human consumption. However, further target-oriented 
research is needed to overcome negative aspects like bitter taste (Cho et al., 2004), possible 
interactions with other food components, or allergies (Ngo et al., 2011). 
In terms of commercial applications, the investigation of mussel lipids has shown much more 
progress compared to mussel proteins. As exemplified by Lyprinol
®
, a dietary supplement product 
containing the oil of the New Zealand green-lipped mussel, many dietary supplement products have 
been brought to the market. Major health claims of these products are related to beneficial effects in 
the treatment of arthritic conditions. The lack of any significant adverse effects and efficient relief 
from pain and stiffness appear to be key factors behind the success of Lyprinol
®
 and similar mussel 
oil products as readily available over-the-counter-products worldwide. 
The bioactive potential of mussel carbohydrates has been explored to a lesser extent in 
comparison to the other two classes of metabolites, however existing studies point out promising 
immune-modulating or antioxidant bioactivities especially for mussel-derived polysaccharides 
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(Ovodova et al., 1992; Xu et al., 2008). So far no commercial applications have been reported for 
these bioactives. In summary, primary metabolites from marine mussels of the genus Mytilus and 
Perna have shown promising results. Hence, they represent invaluable sources for the development 
of functional foods, food ingredients, or pharmaceuticals. Further advances in processing and 
analytical technologies as well as a more interdisciplinary research focus are expected to promote a 
straightforward and targeted development of health beneficial products in the near future. 
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Captions 
Figure 1. Comparison of number of selected publications dealing with bioactives from marine mussels 
categorised in four classes, i.e. proteins/peptides/amino acids (AA), lipids, carbohydrates, and miscellaneous. 
Figure 2. Evaluation of number of publications which report bioactive properties related to three major 
classes of mussel compounds. Peptides, lipids, and carbohydrates are differentiated in different shades of 
grey. 
Figure 3. Pictures of M. edulis (A, whole mussel; B, shells) and P. canaliculus (C, whole mussel; D, shells). 
Figure 4. Structures of P. canaliculus PUFAs (omega-3) and novel anti-inflammatory furan fatty acids in 
comparison to omega-6 PUFAs eicosadienoic acid (EA) and arachidonic acid (AA).  
Figure 5. Down-regulation of the key enzymes in the arachidonic acid cascade by lipid extract of P. 
canaliculus (shown in red) resulting in a reduced formation of inflammatory mediators (figure modified from 
(Halpern, 2000). HETE, hydroxyeicosatetraenoic acid; HPETE, hydroperoxyeicosatetraenoic acid; LT, 
leukotriene; PGI2, prostacyclin; TX, thromboxane. 
Figure 6. Chemical structures of shellfish biotoxins: (a) okadaic acid; (b) ciguatoxin and brevetoxin A; (c) 
spirolide C and gymnodimine; (d) saxitoxin; and (e) domoic acid. 
 
 
Table 1. Overview on bioactive proteins, peptides, and amino acids derived from marine mussels. 
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Table 1 
Biological activity - name of 
bioactive protein/peptide 
Sequence and  molecular weight Mussel 
species 
Origin/product Reference(s) 
Antioxidant     
Mussel-derived radical scavenging 
peptide (MRSP) 
HFGDPFH 
(962 Da) 
ME Fermented sauce (Rajapakse et al., 2005) 
N.g. LVGDEQAVPAVCVP 
(1.59 kDa) 
MC In vitro 
gastrointestinal 
digest 
(Jung et al., 2007) 
N.g. FGHPY 
(620 Da) 
ME Fermented sauce (Jung, Rajapakse, & Kim, 2005) 
Antimicrobial     
Mytilus defensin A GFGCPNDYCHRHCKSIPGRXGGYCGGXHRLRCTCYR 
(~ 4 kDa) 
ME Blood (Charlet et al., 1996) 
Mytilus defensin B GFGCPNDYPCHRHCKSIPGRYGGYCGGXHRLRCTC— 
(~ 4 kDa) 
ME Blood (Charlet et al., 1996) 
MGD-1 GFGCPNNYQCHRHCKSIPGRCGGYCGGWHRLRCTCYRCG  
(4.4 kDa) 
MG Hemocytes (Hubert, Noel, & Roch, 1996; Mitta et al., 1999; Yang et al., 2000) 
MGD-2 GFGCPNNYACHQHCKSIRGYCGGYCASWFRLRCTCYRCG 
(4.4 kDa) 
MG Hemocytes (Mitta, Hubert, et al., 2000; Mitta et al., 1999; Yang et al., 2000) 
Mytilin A GCASRCKAKCAGRRCKGWASASFRGRCYCKCFRC 
(~ 4 kDa) 
ME, MG Hemocytes (Charlet et al., 1996; Löfgren et al., 2009; Mitta, Vandenbulcke, et al., 
2000) 
Mytilin B SCASRCKGHCRARRCGYYVSVLYRGRCYCKCLRC 
(4.0 kDa) 
ME, MG Hemocytes (Charlet et al., 1996; Mitta, Vandenbulcke, et al., 2000) 
Mytilin C SCASRCKSRCRARRCRYYVSVRYGGFCYCRC- 
(4.2 kDa) 
MG Hemocytes (Mitta, Vandenbulcke, et al., 2000) 
Mytilin D GCASRCKAKCAGRRCKGWASASFRRRCYCKCFRC 
(3.9 kDa) 
MG Hemocytes (Mitta, Vandenbulcke, et al., 2000) 
Mytilin G1 VVTCGSLCKAHCTFRKCGYFMSVLYHGRCYCRCLLC 
(~ 4 kDa) 
MG Hemocytes (Mitta, Vandenbulcke, et al., 2000) 
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Biological activity - name of 
bioactive protein/peptide 
Sequence and  molecular weight Mussel 
species 
Origin/product Reference(s) 
Myticin A HSHACTSYWCGKFCGTASCTHYLCRVLHPGKMCACVHCSR 
(4.5 kDa) 
MG Hemocytes (Padhi & Verghese, 2008) 
Myticin B HPHVCTSYYCSKFCGTAGCTRYGCRNLHRGKLCFCLHCSR 
(4.6 kDa) 
MG Hemocytes (Padhi & Verghese, 2008) 
Myticin C QSVACRSYYCSKFCGSAGCSLYGCYLLHPGKICYCLHCSR 
(4.4 kDa) 
MG Hemocytes (Balseiro et al., 2011; Padhi & Verghese, 2008) 
N.g. N.g. 
(9.7 kDa) 
PV Gill homogenate (Chandran, Rameshkumar, & Ravichandran, 2009) 
Anti-inflammatory     
 15 Essential and non-essential amino acids MG Proteic extract (Badiu et al., 2010) 
Antihypertensive     
N.g. EVMAGNLYPG  
(Partial sequence – N-terminal region; 6.5 kDa) 
ME Fermented sauce (Je et al., 2005) 
Antifungal     
Mytimycin DCCRKPFRKHCWDCTAGTPYYGYSTRNIFGCTC---  
(6.5 kDa) 
ME Blood (Charlet et al., 1996) 
Anticoagulant     
N.g. EADIDGDGQVNYEEFVAMMTSK  
(2.5 kDa) 
ME Edible part (Jung & Kim, 2009) 
Anti-thrombin     
Pernin Protein composed of 497 amino acids  
(60 kDa) 
PC Cell-free 
haemolymph 
(Scotti et al., 2001) 
Adhesive for surgical applications     
 Adhesive protein ME Byssus (Ninan et al., 2007) 
ME, M. edulis; MC, M. coruscus; MG, M. galloprovincialis; PC, P. canaliculus; PV, P. viridis; N.g., not given 
